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ORIGINAL ARTICLE
Adverse events in hospitalised cancer patients: a comparison to a general
hospital population
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aDepartment of Oncology and Palliative Medicine, Nordland Hospital Trust, Bodø, Norway; bDepartment of Community Medicine, University
of Tromsø, Tromsø, Norway; cCentre for Quality, Region of Southern Denmark, Middelfart, Denmark; dInstitute of Regional Health Research,
University of Southern Denmark, Odense, Denmark; eDepartment of Clinical Medicine, University of Tromsø, Tromsø, Norway; fCentre for
Clinical Documentation and Evaluation, Northern Norway Regional Health Authority, Tromsø, Norway
ABSTRACT
Background: Patients with cancer are often treated by many healthcare providers, receive complex
and potentially toxic treatments that can increase the risk for iatrogenic harm. The aim of this study is
to investigate whether hospitalised cancer patients are at higher risk of adverse events (AEs) compared
to a general hospital population.
Material and methods: A total of 6720 patient records were retrospectively reviewed comparing AEs
in hospitalised cancer patients to a general hospital population in Norway, using the IHI Global Trigger
Tool method.
Results: 24.2 percent of admissions for cancer patients had an AE compared to 17.4% of admissions of
other patients (p< .001, rr 1.39, 95% CI 1.19–1.62). However, cancer patients did not have a higher rate
of AEs per 1000 patient days compared to other patients, 37.1 vs. 36.0 (p¼ .65, rr 0.94, 95% CI
0.90–1.18). No particular cancer category is at higher risk. The rate of AEs increases by 1.05 times for
each day spent in hospital. For every year increase in age, the risk for AEs increases by 1.3%. Cancer
patients more often have hospital-acquired infections, other surgical complications and AEs related to
medications.
Conclusions: Because of higher age, longer length of stay and surgical treatment, hospitalised cancer
patients experience AEs more often than other patients.
ARTICLE HISTORY
Received 20 January 2017
Accepted 14 March 2017
Introduction
The health care system is a complex environment involving
both system and individual risk factors for iatrogenic harm.
Based on patient characteristics, complexity and seriousness
of the illness, some patients are at greater risk of adverse
events (AEs) [1,2]. The risk of iatrogenic harm increases with
age, length of stay, surgery, emergency services and treat-
ment in intensive care [3]. Patients with cancer are often
treated by a variety of healthcare providers, receive complex
and potentially toxic treatments that could increase the risk
of iatrogenic harm [4]. As new treatments are developed,
new safety hazards will evolve. In addition, cancer patients
may be more prone to AEs due to the disease itself. Accurate
and reliable measurement of AEs remains a challenge in the
patient safety field [5]. The Institute for Healthcare
Improvement’s Global Trigger Tool (IHI GTT) is widely used as
a method to measure and monitor AEs in general hospital-
ised patients [3,6]. Despite this method’s high sensitivity and
specificity in detecting iatrogenic harm, there are limitations
[7–9]. One Danish study raises methodological concerns of
the IHI GTT, not being specific enough in monitoring harm in
cancer patients [10]. Knowledge of patient safety measures in
cancer is limited, and a disease-specific approach could be of
value for targeted improvements in cancer care. The aim of
this study is to investigate whether cancer patients have a
higher risk of AEs compared to a general hospital population
as documented by the IHI Global Trigger Tool.
Material and methods
Study design
The study is a retrospective record review comparing AEs in
hospitalised cancer patients and patients with other diseases.
Setting
The study was performed at a public health trust in Norway.
Nordland Hospital Trust has three somatic hospitals: one cen-
tral and two smaller district hospitals, with a total of 524
beds. Cancer patients are treated and hospitalised in all three
hospitals, but only the central hospital has a separate depart-
ment of oncology. The oncology department provides ambu-
latory chemotherapy, palliative care and radiotherapy. Cancer
surgery is primarily performed at the Central Hospital in
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Bodø. None of the hospitals has a separate oncological
inpatient unit, so cancer patients are admitted to other
department depending on the origin of their cancer.
Study population
Since 2010, all hospitals in Norway are required to review a
minimum of 20 randomly selected medical records per month
using the IHI GTT method [11]. Nordland Hospital Trust chose
from the start to review 140 records monthly to achieve
more accurate measurement and better support for local
improvement initiatives [12]. From 1 January 2010 to 31
December 2013, a total of 6720 records were reviewed using
the IHI GTT method. Ten patient records were randomly
sampled, block randomised twice monthly from the discharge
list of seven units in the trust (surgery, orthopaedics, internal
medicine, gynaecology/obstetrics, neurology/others and the
district hospitals of Lofoten and Vesterålen). Patients below
the age of eighteen, patients with a length of stay less than
twenty-four hours or patients admitted primarily for psychi-
atric conditions or rehabilitation were excluded [12–14]. Our
analysed sample accounts for 8.5% of the eligible discharges
of inpatients from the health trust in the study period.
Cancer patients were identified by matching the patient ID
number in the sample to cancer diagnosis in the discharge
lists of the hospitals. From the total sample size of 6720
records, 812 (12.1%) of the patients had cancer as primary or
secondary diagnosis on discharge classified by ICD-10. Age,
gender, length of stay, type of admission, hospital, depart-
ment and cancer characteristics were obtained (Figure 1).
Review method
The review was done according to the Norwegian version
of the IHI GTT manual. The Norwegian version is identical to
the IHI GTT, except for minor changes to three triggers
[13,14]. All review teams were trained according to the IHI
protocol for GTT analyses. Seven different teams reviewed
records from their unit in the trust. All review teams consist
of one physician and two nurses, and only had minor
changes in composition during the study period. The review
was performed as in two-stages. Two nurses reviewed all
records independently and then together reached consensus
on presence, category and severity of AEs. The physician
then authenticated their findings. Cancer patients were
reviewed together with the other patients, and separated
afterwards for the study. AEs were defined as ‘Unintended
physical injury resulting from or contributed to by medical
care that requires additional monitoring, treatment or hospi-
talization, or that results in death.’ [14] The severity of AEs
was categorised according to the NCC MERP index [15]
(Table 1). AEs were before reviewing grouped into 23 catego-
ries according to recommendations in the Norwegian GTT
manual. For statistical purpose, the categories were aggre-
gated into eight main categories in the study: hospital-
acquired infections, surgical complications, bleeding/throm-
bosis, patient fall/fracture, medication harm, obstetric harm,
pressure ulcer and others.
Statistical analysis
Demographic variables were compared using the Pearson’s
Chi-squared test and the Mann–Whitney U-test. Incidence
rates of AEs, severities and categories were compared using
negative binominal regression in generalised linear models.
Rates were calculated as AEs per 1000 patient days and as
percentage of admissions with one or more AEs. Log patient
days were used as offset variable to compare rates per 1000
patient days. For admissions with AEs, the offset variable was
set to a fixed value of zero. In addition, we adjusted for dem-
ographical variables: age, gender, length of stay, type
of admission, hospital, department and year of discharge.
A p-value< .05 was deemed statistically significant. Data
were analysed with IBM SPSS V23.0.
Results
Demographic characteristics
According to the discharge index, cancer diagnosis accounts
for 10.8% of patients admitted to the total hospitals popula-
tion. In our sample, cancer patients represent a stable rate of
12% per year, evenly distributed between the hospitals.
Cancer patients are 10.2 years older, stay 2.27 days longer in
hospital and are more often male than the general hospital
population. Cancer patients are more often admitted elec-
tively, and are more likely to be admitted to a surgical
department than other patients (Table 2).
Cancer of the large bowel (15%), prostate (13%) and lung
(12%) are most common. Gastrointestinal and urinary cancer
Figure 1. Overview population and study design.
ACTA ONCOLOGICA 1219
counts for 51% of the cancers. 59% of the cancer patients
have metastases and 65% are in a palliative setting. A major-
ity of the patients (51%) received ordinary medical treatment.
Thirty-five percent had surgery or other minor procedures
such as biopsies, stent insertion or pleural draining. Fifteen
percent received cancer-related treatments such as chemo-
therapy or radiation (Table 3).
Comparison of AEs
An AE was recorded in 24.2% of admissions for cancer
patients compared to 17.4% of admissions for other patients
(p< .001, rr 1.39, 95% CI 1.19–1.62). Estimating the rate per
1000 patient days, cancer patients have no higher rate of AEs
than other patients, 37.1 vs. 36.0 (p¼ .65, rr 0.94, 95% CI
0.90–1.18). Adjusted for demographic variables, there is still
no significant difference between the groups but the inci-
dence rate of AEs decreases, 24.4 vs. 26.0 (p¼ .35, rr 0.94,
95% CI 0.82–1.07) (Table 4).
For the total sample, the rate of AEs is 1.05 times greater
for each extra day spent in hospital (p< .001, 95% CI
1.04–1.06). For every year increase in age, the risk of an AE
increases by 1.3%, (p< .001, rr 1.013, 95% CI 1.01–1.02).
Acute admission increases the risk of AEs by 17% (p¼ .01, rr
1.17, 95% CI 1.039–1.327). Admission to a surgical or gynae-
cology department increases the rate of AEs by more than
50%. The district hospital in Lofoten has a 30% lower rate of
AEs (p< .001, rr 0.70, 95% CI 0.580–0.850) (Table 5).
Cancer patients having surgery or minor procedures have
an increased rate of 68% for AEs compared to other patients
with cancer (p¼ .007, rr 1.68, 95% CI of 1.15–2.46). Receiving
treatment with curative intent increases the rate of AEs by
74% (p¼ .002, rr 1.74, CI 95% 1.24–-2.46). However, rates are
similar for the different cancer categories (Table 3).
Severity of AEs
Most of the AEs are of temporary harm, severity E and F for
both cancer patients (88%) and others (89%). Adjusted for
demographic variables, there is no difference in severity per
admission or per 1000 patient days between cancer patients
and other patients.
Type of AEs
Cancer patients more often than other patients experience
hospital-acquired infections, 11.5 vs. 7.6% per admission
(p¼ .001, rr 1.51, 95% CI 1.20–1.91). Cancer patients primarily
have lower respiratory infections (4.5 vs. 2.8%) and other
infections (3.2 vs. 1.6%). Cancer patients have a 54% greater
risk than other patients of surgically related AE per admis-
sion, 8.7 vs. 5.7% (p¼ .002, rr 1.54, 95% CI 1.18–2.00). This is
primarily due to events termed ‘other operative
complications’, 3.1 vs. 1.9%. Cancer patients experience twice
the rate of medication-related AE per admission, 34 vs. 17%
(p¼ .005, rr 2.03, 95% CI 1.23–2.91). Adjusted for length of
stay and other demographic variables, cancer patients have a
58% higher risk for medication-related AEs per 1000 patient
days, 2.6 vs. 1.6 (p¼ .045, rr 1.58, 95% CI 1.01–2.46) (Table 6).
Discussion
Hospitalised cancer patients have a 39% greater risk of expe-
riencing an AE compared to other patients, but this is due to
older age, longer length of stay and surgery rather than the
cancer itself. There is no difference in occurrence of AEs by
type of cancer, but patients receiving treatment with curative
intent and undergoing surgery have a higher rate of AEs.
Length of stay is the main risk factor for experiencing an
AE, increasing the risk with 5.1% for each day spent in hos-
pital. In our study, cancer patients stay 2.27 days longer in
hospital, increasing the risk for AEs by 11.5%. Other studies
have shown that there is a strong correlation between length
of stay and rate of AEs [7,16]. The average length of stay in
Norway for all hospitalised patients in 2013 was 5.6 days and
6.1 days for cancer patients [17]. Our study correlates with
findings for the overall hospital population, while our cancer
patients are admitted two days longer than the national
average. Increased rates of AEs can both be the cause for or
a consequence of longer length of stay [16,18]. Our study
was not designed to clarify this question.
A meta-analysis of AEs measured by the GTT, found an aver-
age of 29% of admissions with at least one AE and an average
of 61 AEs per 1000 patient days [3]. These average rates are
higher than we found in our study, but comparing rates are dif-
ficult due to differences in study population and case mix. A
Norwegian national GTT measurement shows that the total
Table 1. Severity grading of AEs.
Category
E Temporary harm that required intervention
F Temporary harm that required initial or prolonged hospitalization
G Permanent patient harm
H Intervention required necessary to sustain life
I Harm contributed to or resulted in patient death
Note: Severity categories according to the National Coordinating Council for
Medication Error Reporting and Prevention Index (NCC MERP).
Table 2. Characteristics in 6720 patients.
Parameter
Cancer patients
n¼ 812
Other patients
n¼ 5908
Mean age, years (SD) 70.0 (13.0) 59.7 (21.5)
Min.–Max. 20–102 18–102
Mean length of stay, days (SD) 8.4 (9.6) 6.1 (7.0)
Min.–Max. 1–81 1–122
Gender N (%)
Female 364 (44.8) 3 642 (61.6)
Male 448 (55.2) 2 266 (38.4)
Type of admission N (%)
Acute 512 (63.1) 4 291 (72.9)
Planned 300 (36.9) 1 617 (27.4)
Years 2010–2013 Range (%) 11.3–12.4 87.6–87.9
Hospital range (%)
Central Hospital Bodø 604 (12.6) 4 196 (87.4)
District Hospital Lofoten 106 (11.0) 854 (89.0)
District Hospital Vesterålen 102 (10.6) 858 (89.4)
Department N (%)
Internal medicine 236 (29.1) 1 689 (28.6)
Surgery 457 (56.3) 2 290 (38.8)
Gynaecology 36 (4.4) 1 063 (18.0)
Neurology 40 (4.9) 599 (10.1)
Other departments 43 (5.3) 266 (4.5)
p< .001.
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harm rate on average was 15.96% for the same time period
[19]. This is lower than our rate and could be due to the fact
that Nordland Hospital Trust reviews seven times more patient
records than other hospitals in Norway [12]. Our results are
consistent with findings from Denmark where similar rates of
AEs were detected in cancer patients [20].
The district hospital of Lofoten has a 30% lower rate of AE
(13.4 per 1000 patient days). This is significantly lower than
the Central Hospital of Bodø (17.7 per 1000 patient days) but
not much lower than the Local Hospital of Vesterålen (14.6
per 1000 patients days). These findings correlate with the
size of the hospitals and are most likely explained by the fact
that the local hospitals perform less surgery and have a
lower DRG index.
Admissions with AEs tell us what happens to the patients,
while AEs per 1000 patient days adjusts for one important
risk factor, and makes it more appropriate for monitoring
over time. In addition, our data show that adjusting for other
characteristics such as age, gender, type of admission and
department further decreases the rate of AEs per 1000
patient days to 37.1 vs. 24.4 and 36.0 vs. 26.0 respectively.
This implies that demographic characteristics significantly
affect the rate of AEs. Demographic variables may vary and
especially affect small sample sizes as recommended
reviewed in the IHI GTT method. Not adjusting for demo-
graphic variables therefore raises concern about the GTT
methods ability to detect real change when monitoring AEs
even within an organisation.
The age of patients is a main risk factor for AEs [7,21]. Our
results indicate that for every year increase in age, the risk of
an AE increases by 1.3%. In our sample, cancer patients are
10.2 years older than other patients, increasing the risk by
13%. Age is also a strong determinant of cancer risk and an
Table 3. Cancer characteristics and rate of AEs.
Admissions with AEs AEs per 1000 patient days
Frequency (%) Percent p Value Rate p Value
Cancer categories .520 .102
Gastrointestinal 210 (25.9) 26.2 35.9
Urinary/Male genitalia 208 (25.6) 25.0 39.4
Respiratory 95 (11.7) 29.5 32.7
Lymphoma/Haematological 85 (10.5) 18.8 21.0
Breast 65 (8.0) 23.1 46.4
Gynaecology 51 (6.3) 17.6 22.7
ENT 40 (4.9) 17.5 22.9
Others 58 (7.1) 25.9 17.0
Metastases .028 .118
Lymphatic 122 (15.0) 36.5 45.2
Organ 356 (43.8) 21.2 28.5
None 334 (41.1) 23.9 32.3
Treatment intention .022 .002
Curative 281 (34.6) 30.4 44.9
Palliative 531 (65.4) 21.3 25.8
Treatment .149 .022
Surgery 281 (34.6) 30.9 44.2
Chemotherapy 77 (9.5) 24.9 31.1
Radiation 40 (4.9) 27.2 19.2
None 414 (51.0) 20.4 26.3
Note: Estimated using negative binominal regression adjusted for demographic characteristics.
Table 4. Incidence rates for AEs.
Admissions with AEs AEs per 1000 patient days
Frequency Percent CI 95% p Valuea Frequency Rate CI 95% p Valuea
Cancer patients N¼ 812 197 24.2 20.7–28.2 .000 253 37.1 32.8–42.0 .651
Other patients N¼ 5908 1027 17.4 16.3–18.6 1295 36.0 34.1–38.0
Note: Comparison of frequency and rate not adjusted for any other variables.
aNegative bi-nominal regression.
Table 5. Incidence rate for AEs.
Parameter
AEs per 1000
patient days 95% CI Exp(B) p Valuea
Patients
Cancer 24.4 20.7–28.7 0.937 .349
Others 26.0 23.2–29.2 1
Age 1.013 .000
Gender
Male 14.9 12.9–17.3 1.010 .851
Female 15.3 13.3–17.7 1
Type of admission
Acute 18.5 16.2–21.1 1.174 .010
Planned 12.4 10.5–14.6 1
Year
2010 27.2 15.3–21.0 1.049 .511
2011 25.2 14.4–19.8 0.973 .707
2012 22.7 11.0–15.4 0.875 .087
2013 25.9 12.0–17.6 1
Hospital
Central Hospital Bodø 17.7 15.8–19.9 0.991 .906
District Hospital Lofoten 13.4 11.1–16.3 0.702 .000
District Hospital Vesterålen 14.6 12.0–17.6 1
Department
Internal medicine 13.5 11.7–15.7 0.984 .929
Surgery 23.6 21.1–26.6 1.745 .002
Gynaecology 17.8 14.2–22.4 1.562 .025
Neurology 13.3 10.5–16.9 0.755 .155
Others 10.4 7.21–15.1 1
Note: Rates adjusted for age, gender, type of admission, year, hospital and
department.
aNegative Binominal regression with fixed age 60.9 years and length of stay
6.37 days.
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ageing population will increase the cancer rate per se. This
implies that more patients will need cancer treatment, and
thus escalate the burden on cancer care, and risk of AEs in
our hospitals [22].
Our results are consistent with other studies indicating
that admission to a surgical department and having surgery
increases the rate of AEs [16,23]. A majority of our cancer
patients are admitted to surgical departments and 36% have
surgery. Since surgery is the main curative treatment for can-
cer, this partly explains why receiving treatment with curative
intent increase the risk for AEs.
In accordance with other GTT studies on cancer patients,
cancer patients more often experience AEs related to hos-
pital-acquired infections (lower respiratory infections and
other infections), surgical complications and medication harm
[24,25]. Adjusted for length of stay and other demographic
variables, the only type of AE cancer patients experience
more often is harm related to medication. Unfortunately, we
do not know if these AEs relate to chemotherapy or other
medications. The GTT method only registers if an AEs has
occurred, and does not identify supplementary information
such as type of medication, dosage or polypharmacy that
could identify underlying causes and benefit further improve-
ment work. Many of the categories are heterogeneous and
need to be more specific to provide meaningful data for
improvement in cancer care.
Our sample is representative for a general hospitalised
population and shows that the majority of cancer patients
receive surgery or ordinary medical treatment. Only 15% of
the patients receive cancer related treatment such as
chemotherapy or radiation. Our study shows that cancer in
itself is not a risk factor for AEs, and hospitalised cancer
patients seem to have the same general risk factors for AEs as
other patients. Having cancer should therefore not affect the
reliability of the GTT method when used in an ordinary in-
hospital population. The fact that only 15% of hospitalised
cancer patients receive medical or radiation related cancer
treatments indicates that monitoring AEs related to these
treatments preferably should be done in an ambulatory
setting.
Limitations
The GTT as a method has limitations that most likely also
apply to our study. The reliability of record reviewing is mod-
erate to sustainable when done by a small group of
reviewers [9]. In our study, seven different teams (21
reviewers) did the review. Even though the teams had the
same training, where fairly consistent and reviewed 960
records during the period, there is a possibility that their
judgement of what is an AE, severity grading and classifica-
tion could vary between the teams and deviate over time.
Another GTT study in the health trust has shown substantial
agreement between teams, but our study was not designed
to look at inter-rated reliability [12]. As a retrospective record
review method, the GTT may have limitations regarding
documentation bias, since reviewers must rely on information
recorded in the patient charts. This could be avoided per-
forming a real time observation study, but does not seem
feasible to use as a method to measure AEs over time.
Table 6. Comparing type of AEs per admission.
Cancer patients Other patients
Admission with AEs cancer vs.
other patients
Admissions with AEs adjusteda
cancer vs. other patients
N (%) N (%) Exp(B) p Value CI 95% Exp(B) p Value CI 95%
Hospital acquired infections 94 (11.5) 451 (7.6) 1.51 .001 1.20–1.91 1.03 .848 0.80–1.32
Urinary tract infection 29 (3.6) 180 (3.0)
Central venous catheter infection 1 (0.1) 4 (0.1)
Ventilator associated pneumonia 1 (0.1) 9 (0.2)
Other infections 37 (4.5) 164 (2.8)
Lower respiratory infections 26 (3.2) 94 (1.6)
Surgical complications 71 (8.7) 335 (5.7) 1.54 .002 1.18–2.00 0.99 .920 0.74–1.31
Infection after surgery 12 (1.5) 59 (1.0)
Respiratory complications after surgery 4 (0.5) 13 (0.2)
Return to surgery 8 (1.0) 46 (0.8)
Injury, repair or removal of organ 6 (0.7) 19 (0.3)
Bleeding after surgery 11 (1.3) 82 (1.4)
Any other operative complication 25 (3.1) 113 (1.9)
Switch in surgery 5 (0.6) 3 (0.1)
Bleeding and thrombosis 20 (5.6) 142 (2.4) 1.02 .933 0.64–1.64 0.74 .228 0.45–1.21
Thrombosis-embolism 5 (0.6) 27 (0.5)
Bleeding 15 (1.8) 115 (1.9)
Patient fall and fracture 10 (1.2) 87 (1.4) 0.83 .586 0.43–1.61 0.65 .217 0.33–1.29
Patient fall 9 (1.1) 45 (0.8)
Fracture 1 (0.1) 42 (0.7)
Medication harm 28 (3.4) 100 (1.7) 2.03 .001 1.33–3.10 1.87 .005 1.20–2.91
Obstetric harm 0 (0) 36 (0.6)
Pressure ulcers 7 (0.9) 37 (0.6) 1.37 .446 0.61–3.09 1.05 .904 0.45–2.45
Others 23 (2.8) 107 (1.8) 1.56 .057 0.99–2.46 1.42 .146 0.88–2.29
Allergy 4 (0.5) 23 (0.4)
Medical technical harm 5 (0.6) 14 (0.2)
Deterioration of chronic illness 6 (0.7) 15 (0.3)
Others 8 (1.0) 55 (0.9)
Note: AEs grouped into 23 categories and aggregated into eight main categories for statistical analysis. Estimated differences using negative binominal
regression.
aResults adjusted for demographic characteristics.
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Nonetheless, GTT is one of the few tools measuring AEs in
health care, and is recommended for use in many organisa-
tions worldwide. Another limitation of our study is not
adjusting for comorbidities, especially since the age differ-
ence between the groups is more than 10 years and cancer
patients therefore could have more comorbidity.
Conclusions
Hospitalised cancer patients more often than other patients
experience AEs, but this is due to older age, longer length of
stay and surgery rather than the cancer itself. In addition, our
study shows that demographic characteristics affect the rate
of AEs, and raise reliability concerns regarding the GTT meth-
od’s ability to detect real change when monitoring AEs over
time. When measuring AEs in a general hospitalised popula-
tion, the GTT method seems just as reliable for cancer
patients as other patients. Since only a small amount of hos-
pitalised cancer patients receives medical or radiation related
cancer treatments, we suggest that a method for measuring
AEs in an outpatient cancer setting should be developed.
Developing cancer specific categories for AEs would also be
essential in order to provide meaningful data for improve-
ment in cancer care.
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